Full text is available at the source.
Abstract
AT4-13CRA LNPs achieved approximately 15.1-fold higher splenic expression compared to a tested formulation.
- Effective mRNA cancer vaccination relies on productive antigen expression in lymphoid antigen-presenting cells.
- The study developed a library of 40 retinoic-acid-derived ionizable lipids (RAILs) to enhance mRNA expression.
- AT4-13CRA LNPs were identified as the most effective formulation based on spleen-to-liver reporter expression ratios.
- The enhanced expression was linked to reduced retention of mRNA in lysosomes and lower activation of certain inflammatory pathways.
- In mouse models, AT4-13CRA LNPs promoted effective responses in splenic macrophages and dendritic cells, resulting in stronger CD8+ T-cell and antibody responses.
- These findings suggest a method for creating targeted mRNA vaccines that focus on spleen-specific immune responses.
Simplified